CATALYST PHARMACEUTICALS INC (CPRX)

US14888U1016 - Common Stock

21.62  +0.02 (+0.09%)

After market: 21.81 +0.19 (+0.88%)

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (12/24/2024, 8:04:44 PM)

After market: 21.81 +0.19 (+0.88%)

21.62

+0.02 (+0.09%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%220.69%
Sales Q2Q%25.33%
CRS83.23
6 Month39.57%
Overview
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Ins Owners5.97%
Inst Owners83.84%
Market Cap2.58B
Shares119.27M
PE18.32
Fwd PE13.34
Dividend YieldN/A
Analysts87.14
Short Float %5.44%
Short Ratio6.58
IPO11-08 2006-11-08
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CPRX Daily chart

Company Profile

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 167 full-time employees. The company went IPO on 2006-11-08. The firm is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The firm is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

Company Info

CATALYST PHARMACEUTICALS INC

355 Alhambra Circle, Suite 801

Coral Gables FLORIDA 33134

P: 13055292522

CEO: Patrick J. McEnany

Employees: 167

Website: https://catalystpharma.com/

CPRX News

News Imagea day ago - Investor's Business DailyNeurocrine Biosciences Stock Sees RS Rating Upgrade

Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71.

ChartMill News Imagea day ago - ChartmillFor those who appreciate value investing, NASDAQ:CPRX is a compelling option with its solid fundamentals.

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

ChartMill News Image8 days ago - ChartmillWhy NASDAQ:CPRX Is a Standout High-Growth Stock in a Consolidation Phase.

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout.

News Image9 days ago - Catalyst Pharmaceuticals, Inc.Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Image9 days ago - Catalyst Pharmaceuticals, Inc.Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (

News Image14 days ago - Investor's Business DailyNewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

CPRX Twits

Here you can normally see the latest stock twits on CPRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example